{"nctId":"NCT01853553","briefTitle":"Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","startDateStruct":{"date":"2013-07"},"conditions":["ADPKD"],"count":61,"armGroups":[{"label":"Spironolactone","type":"EXPERIMENTAL","interventionNames":["Drug: Spironolactone"]},{"label":"Sugar Pill","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Sugar pill"]}],"interventions":[{"name":"Spironolactone","otherNames":[]},{"name":"Sugar pill","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 20-55 years;\n* Adults with ADPKD diagnosis based on Ravine criteria aged ≥ 30 years\n* Estimated glomerular filtration rate ≥ 60 ml/min/1.73m2\n* Hypertension defined as a systolic BP \\> 130 mm Hg and/or diastolic BP \\> 80 mmHg based on 3 separate measurements within the past year and currently on a minimum dose of an angiotensin converting enzyme inhibitor (minimum dose 10 mg P.O qd) or angiotensin receptor blocker (i.e., Losartan 25 mg P.O qd)\n* If using antioxidants and/or omega-3 fatty acids, must discontinue 4 weeks prior to participation\n* Free from alcohol dependence or abuse\n* Mini-mental state examination score ≥ 24; ability to provide informed consent\n* BMI \\< 40 kg/m2 (FMD measurements can be inaccurate in severely obese patients)\n* Not taking medications that interact with agents administered during experimental sessions (e.g., sildenafil interacts with nitroglycerin)\n\nExclusion Criteria:\n\n* • Average serum potassium \\>5.5 millequivalents or any single serum potassium \\> 6.0 millequivalents within the previous 6 months\n\n  * Receiving an aldosterone antagonist within the previous 6 months\n  * Use of a potassium sparing diuretic or any other drug that could contribute to hyperkalemia\n  * Uncontrolled hypertension\n  * Current smokers or history of smoking in the past 12 months\n  * History of liver disease\n  * History of heart failure (EF \\< 35%)\n  * History of hospitalizations within the last 3 months\n  * Active infection or antibiotic therapy\n  * Warfarin use\n  * Immunosuppressive therapy within the last year\n  * Pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Flow Mediated Dilation at 6 Months.","description":"FMD will be determined using high-resolution ultrasonography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.2"},{"groupId":"OG001","value":"-0.4","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Vascular Stiffness at 6 Months.","description":"Aortic pulse wave velocity, a measure of large elastic arterial stiffness, and carotid compliance, a measure of large artery distensibility, will be determined. A transcutaneous custom tonometers (Noninvasive Hemodynamics Workstation, Cardiovascular Engineering Inc., Norwood, MA) will be positioned at the aorta and femoral artery to measure pulse wave velocity, and carotid artery compliance (and the β-stiffness index, a more blood pressure independent measure of local arterial stiffness) will be measured non-invasively using simultaneous high-resolution ultrasonography and applanation tonometry). Higher values correspond to greater stiffness.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37","spread":"78"},{"groupId":"OG001","value":"-1","spread":"89"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Circulating Markers of Oxidative Stress at 6 Months.","description":"All markers of oxidative stress will be assayed by multiplexed validated liquid chromatography (LC)/ LC-mass spectrometry (MS)/ MS.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":[]}}}